Literature DB >> 16238977

Metastatic prostate cancer with a normal prostate-specific antigen level.

Isabel Ruiz-Martín1, César A Rodríguez-Sánchez, Alberto Ocaña-Fernández, Javier del Valle-Zapico, Diego Soto de Prado-Otero, Juan J Cruz-Hernández.   

Abstract

Prostate-specific antigen (PSA) is the most commonly used tumour marker for prostate cancer, both in screening and in follow-up. However, there are many false positive increases in the presence of other prostate diseases and, currently, there is no consensus regarding sensitivity and specificity of the PSA test, nor what constitutes the upper limit of normality. We report a case of a 67-year-old patient with metastatic prostate cancer who, with increased level of alkaline phosphatase and normal PSA, showed clinical and radiological evidence of progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238977     DOI: 10.1007/bf02716588

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  9 in total

1.  Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma.

Authors:  Kishor Mistry; Greg Cable
Journal:  J Am Board Fam Pract       Date:  2003 Mar-Apr

2.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

Review 3.  Screening for prostate cancer with prostate-specific antigen. An examination of the evidence.

Authors:  S H Woolf
Journal:  N Engl J Med       Date:  1995-11-23       Impact factor: 91.245

Review 4.  Biochemical markers and skeletal metastases.

Authors:  L M Demers; L Costa; A Lipton
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

5.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

6.  Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Authors:  Jason S Krumholtz; Gustavo F Carvalhal; Christian G Ramos; Deborah S Smith; Phataraporn Thorson; Yan Yan; Peter A Humphrey; Kimberly A Roehl; William J Catalona
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

7.  Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population.

Authors:  K Komatsu; N Wehner; A F Prestigiacomo; Z Chen; T A Stamey
Journal:  Urology       Date:  1996-03       Impact factor: 2.649

Review 8.  Biology of prostate-specific antigen.

Authors:  Steven P Balk; Yoo-Joung Ko; Glenn J Bubley
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

  9 in total
  1 in total

Review 1.  Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.

Authors:  A Valentino; P Reclusa; R Sirera; M Giallombardo; C Camps; P Pauwels; S Crispi; C Rolfo
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.